Valar Labs

Valar Labs develops AI-based diagnostics that interpret solid tumours, generating insights intended to inform treatment decisions by physicians and patients. Its work sits at the intersection of artificial intelligence, computational histology and digital pathology, applied to oncology diagnostics and biomarker development. The company has raised $26M in funding.

The company's product line addresses two cancer types. Vesta is a bladder cancer diagnostic that predicts response to BCG treatment using routine histology, without additional invasive procedures; it is described as the only bladder cancer diagnostic to predict BCG treatment response from routine histology. Vitara is a pancreatic cancer test that predicts which patients are more likely to benefit from specific chemotherapy regimens.

Its research underpinning includes published AI biomarker work in European Urology and the Journal of Clinical Oncology. The company states a mission of making precision medicine accessible to a broader patient population, with activity spanning oncology, urology, cancer diagnostics, precision medicine and chemotherapy decision support. Further details are available at valarlabs.com.